IP Library Granted Patent US 8,637,470
Granted Patent B2
US 8,637,470 · App. 12/989,688 · Granted Jan 28, 2014

Small humanin-like peptides

Inventors: Pinchas Cohen (Pacific Palisades, CA); Laura J. Cobb (Los Angeles, CA)
Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,470
App. No.
12/989,688
Granted
Jan 28, 2014
Kind
B2
Abstract

Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment.

Claims (8)

1. An isolated small humanin-like peptide (SHLP) consisting of an amino acid sequence at least 90% identical to MGVKFFTLSTRFFPSVQRAVPLWTNS (SEQ ID NO: 9), wherein the SHLP has at least one therapeutic activity selected from the group consisting of:

inhibiting cell death induced by amyloid-beta (Aβ) peptides in Alzheimer's disease,

inhibiting apoptosis in pancreatic β-cells,

stimulating insulin-induced differentiation of adipocytes,

enhancing cellular resistance to environmental stress, and

inhibiting intracellular production of reactive oxygen species (ROS).

2. A pharmaceutical composition comprising (i) a small humanin-like peptide (SHLP) consisting of an amino acid sequence at least 90% identical to MGVKFFTLSTRFFPSVQRAVPLWTNS (SEQ ID NO: 9); and (ii) at least one pharmaceutically acceptable excipient,

wherein the SHLP has at least one therapeutic activity selected from the group consisting of inhibiting cell death induced by amyloid-beta (Aβ) peptides in Alzheimer's disease, inhibiting apoptosis in pancreatic β-cells, stimulating insulin-induced differentiation of adipocytes, enhancing cellular resistance to environmental stress, and inhibiting intracellular production of reactive oxygen species (ROS).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: COHEN, PINCHAS; COBB, LAURA J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 026184/0021 →
Continuity (2)
Provisional Application 61126251 · May 1, 2008
Related Publication 20110039771A1 · Feb 17, 2011